Coeptis Therapeutics (COEPW) Competitors $0.03 0.00 (-8.05%) As of 09/15/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock COEPW vs. ATNFW, SXTPW, DRTSW, APLMW, BCTXW, CDIOW, CELUW, CEROW, CINGW, and CLNNWShould you be buying Coeptis Therapeutics stock or one of its competitors? The main competitors of Coeptis Therapeutics include 180 Life Sciences (ATNFW), 60 Degrees Pharmaceuticals (SXTPW), Alpha Tau Medical (DRTSW), Apollomics (APLMW), BriaCell Therapeutics (BCTXW), Cardio Diagnostics (CDIOW), Celularity (CELUW), CERo Therapeutics (CEROW), Cingulate (CINGW), and Clene (CLNNW). These companies are all part of the "biotechnology" industry. Coeptis Therapeutics vs. Its Competitors 180 Life Sciences 60 Degrees Pharmaceuticals Alpha Tau Medical Apollomics BriaCell Therapeutics Cardio Diagnostics Celularity CERo Therapeutics Cingulate Clene Coeptis Therapeutics (NASDAQ:COEPW) and 180 Life Sciences (NASDAQ:ATNFW) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership. Does the media refer more to COEPW or ATNFW? In the previous week, Coeptis Therapeutics had 1 more articles in the media than 180 Life Sciences. MarketBeat recorded 1 mentions for Coeptis Therapeutics and 0 mentions for 180 Life Sciences. Coeptis Therapeutics' average media sentiment score of 1.89 beat 180 Life Sciences' score of 0.00 indicating that Coeptis Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Coeptis Therapeutics Very Positive 180 Life Sciences Neutral Which has stronger valuation and earnings, COEPW or ATNFW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoeptis Therapeutics$263.56KN/AN/AN/AN/A180 Life SciencesN/AN/AN/AN/AN/A Is COEPW or ATNFW more profitable? Company Net Margins Return on Equity Return on Assets Coeptis TherapeuticsN/A N/A N/A 180 Life Sciences N/A N/A N/A SummaryCoeptis Therapeutics beats 180 Life Sciences on 3 of the 3 factors compared between the two stocks. Get Coeptis Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COEPW and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding COEPW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COEPW vs. The Competition Export to ExcelMetricCoeptis TherapeuticsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$238.03M$5.80B$10.18BDividend YieldN/A3.78%5.73%4.61%P/E RatioN/A41.2574.8626.39Price / SalesN/A4,870.38543.01125.40Price / CashN/A13.1925.8129.91Price / BookN/A126.0413.256.28Net IncomeN/A-$90.99M$3.29B$270.38M7 Day PerformanceN/A1.41%0.07%1.89%1 Month PerformanceN/A21.60%4.60%6.01%1 Year PerformanceN/A686.15%72.96%25.26% Coeptis Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COEPWCoeptis TherapeuticsN/A$0.03-11.7%N/A+49.4%$0.00$263.56K0.004Gap UpATNFW180 Life SciencesN/A$0.10-43.6%N/A+1,107.9%$0.00N/A0.007Gap UpHigh Trading VolumeSXTPW60 Degrees PharmaceuticalsN/A$0.05-5.7%N/AN/A$0.00$641.41K0.002Gap DownDRTSWAlpha Tau MedicalN/A$0.30+0.7%N/AN/A$0.00N/A0.0080Gap DownAPLMWApollomicsN/A$0.02-3.2%N/A+107.8%$0.00N/A0.0059News CoverageShort Interest ↓Gap DownBCTXWBriaCell TherapeuticsN/A$0.03+4.6%N/A-83.4%$0.00N/A0.008Short Interest ↑CDIOWCardio DiagnosticsN/A$0.02-4.0%N/A-38.0%$0.00$19.51K0.007Positive NewsShort Interest ↓Gap UpCELUWCelularityN/A$0.05+10.9%N/A+173.2%$0.00$44.59M0.00220Gap DownCEROWCERo TherapeuticsN/A$0.01+1.4%N/A+43.0%$0.00N/A0.008Gap DownCINGWCingulateN/A$0.05-4.0%N/A-24.4%$0.00N/A0.0020CLNNWCleneN/A$0.03-4.4%N/A-49.2%$0.00$286K0.00100Gap Down Related Companies and Tools Related Companies ATNFW Competitors SXTPW Competitors DRTSW Competitors APLMW Competitors BCTXW Competitors CDIOW Competitors CELUW Competitors CEROW Competitors CINGW Competitors CLNNW Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COEPW) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe End of Elon Musk…?Jeff has identified five of the past seven number-one performing tech stocks — before they took off. His Tesla...Brownstone Research | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredAmerica’s most terrifying chart?MUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coeptis Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coeptis Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
